CAS 75358-37-1

Linogliride

Description:

Linogliride is a chemical compound classified as a sulfonylurea, primarily used in the management of type 2 diabetes mellitus. It functions as an antihyperglycemic agent by stimulating insulin secretion from the pancreatic beta cells, thereby lowering blood glucose levels. Linogliride is characterized by its ability to enhance insulin sensitivity and improve glycemic control. The compound has a relatively low solubility in water, which can affect its bioavailability and absorption in the body. Its pharmacokinetics involve hepatic metabolism, with metabolites being excreted primarily through the urine. Linogliride may also exhibit some cardiovascular benefits, although its primary role remains in glucose regulation. As with other sulfonylureas, potential side effects include hypoglycemia and weight gain, necessitating careful monitoring of patients. Overall, Linogliride represents a valuable option in the therapeutic arsenal for diabetes management, particularly for individuals who may not achieve adequate control with lifestyle modifications alone.

Formula: C₁₆H₂₂N₄O

InChI: InChI=1/C16H22N4O/c1-19-9-5-8-15(19)18-16(20-10-12-21-13-11-20)17-14-6-3-2-4-7-14/h2-4,6-7H,5,8-13H2,1H3/b17-16-,18-15-

Synonyms:

• Linogliride [USAN:INN]
• N-[(2Z)-1-methylpyrrolidin-2-ylidene]-N'-phenylmorpholine-4-carboximidamide
• Linogliridum
• Linoglirida
• Linogliridum [Latin]
• 4-Morpholinecarboximidamide, N-(1-methyl-2-pyrrolidinylidene)-N'-phenyl-
• Linoglirida [Spanish]
• N-(1-Methyl-2-pyrrolidinylidene)-N'-phenyl-4-morpholinecarboxamidine
• UNII-7E521JYJ4X
• McN 3935

Linogliride

CAS: 75358-37-1

Linogliride: a guanidine derivative, inhibits insulin release, and enhances glucose tolerance by blocking ATP-sensitive K+ channels in pancreatic beta cells.

Formula: C₁₆H₂₂N₄O

Purity: 98%

Color and Shape: Solid

Molecular weight: 286.37

Ref: TM-T25739